{"nctId":"NCT03016312","briefTitle":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen","startDateStruct":{"date":"2017-01-10","type":"ACTUAL"},"conditions":["Prostatic Neoplasms, Castration-Resistant"],"count":759,"armGroups":[{"label":"Atezolizumab + Enzalutamide","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab","Drug: Enzalutamide"]},{"label":"Enzalutamide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enzalutamide"]}],"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq®"]},{"name":"Enzalutamide","otherNames":["Xtandi®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy greater than or equal to (\\>/=) 3 months\n* Histologically confirmed adenocarcinoma of the prostate\n* Known castrate-resistant disease with serum testosterone level less than or equal to (\\</=) 50 nanograms per deciliter (ng/dL) with prior surgical castration or ongoing androgen deprivation for the duration of the study\n* Progressive disease prior to screening by PSA or imaging per PCWG3 criteria during or following the direct prior line of therapy in the setting of medical or surgical castration\n* One prior regimen/line of a taxane-containing regimen for mCRPC or refusal or ineligibility of a taxane-containing regimen\n* Progression on a prior regimen/line of an androgen synthesis inhibitor for prostate cancer\n* Availability of a representative tumor specimen from a site not previously irradiated that is suitable for determination of programmed death-ligand 1 (PD-L1) status via central testing\n* Adequate hematologic and end organ function\n\nExclusion Criteria:\n\n* Prior treatment with enzalutamide or any other newer hormonal androgen receptor inhibitor (e.g., apalutamide, ODM-201)\n* Treatment with any approved anti-cancer therapy, including chemotherapy, immunotherapy, radiopharmaceutical or hormonal therapy (with the exception of abiraterone), within 4 weeks prior to initiation of study treatment\n* Treatment with abiraterone within 2 weeks prior to study treatment\n* Structurally unstable bone lesions suggesting impending fracture\n* Known or suspected brain metastasis or active leptomeningeal disease\n* Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study\n* Active or history of autoimmune disease or immune deficiency\n* Prior allogeneic stem cell or solid organ transplantation\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Positive human immunodeficiency virus (HIV) test, active tuberculosis, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n* Prior treatment with cluster of differentiation (CD)137 agonists or immune checkpoint blockade therapies, including anti Cytotoxic T Lymphocyte-Associated 4 (CTLA4), anti-programmed death 1 (PD-1), and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug, whichever is shorter, prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study\n* History of seizure or any condition that may predispose to seizure within 12 months prior to study treatment, including history of unexplained loss of consciousness or transient ischemic attack","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall Survival is defined as the time from randomization to death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"16.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Survived at Month 6 and 12","description":"OS (Overall Survival is defined as the time from randomization to death from any cause) probability at 6 and 12 months","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.12","spread":null},{"groupId":"OG001","value":"85.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.61","spread":null},{"groupId":"OG001","value":"64.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Symptomatic Skeletal Event (SSE)","description":"An SSE is defined as external beam radiation therapy to relieve skeletal symptoms (including initiation of radium-223 dichloride or other types of radionuclide therapy to treat symptoms of bone metastases), new symptomatic pathologic bone fracture, clinically apparent occurrence of spinal cord compression, or tumor related orthopedic surgical intervention.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"24.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Radiographic Progression-Free Survival (rPFS), as Assessed by the Investigator and Adapted From the PCWG3 Criteria","description":"rPFS is defined as the time from randomization to the earliest occurrence of one of the following:\n\n* A participant is considered to have progressed by bone scan if: The first bone scan with ≥2 new lesions compared to baseline is observed \\< 12 weeks from randomization and is confirmed by a second bone scan taken ≥6 weeks later showing ≥2 additional new lesions (a total of ≥4 new lesions compared to baseline); the date of progression is the date of the first post-treatment scan, OR After the first post-treatment scan, ≥2 new lesions are observed relative to the first post-treatment scan, which is confirmed on a subsequent scan ≥6 weeks later; the date of progression is the date of the post-treatment scan when ≥2 new lesions were first documented.\n* Progression of soft tissue lesions, as defined per PCWG3 modified RECIST v1.1\n* Death from any cause","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Radiographic Progression-Free, as Assessed by the Investigator and Adapted From the PCWG3 Criteria","description":"rPFS is defined as the time from randomization to the earliest occurrence of one of the following:\n\n* A participant is considered to have progressed by bone scan if: The first bone scan with ≥2 new lesions compared to baseline is observed \\< 12 weeks from randomization and is confirmed by a second bone scan taken ≥6 weeks later showing ≥2 additional new lesions (a total of ≥4 new lesions compared to baseline); the date of progression is the date of the first post-treatment scan, OR After the first post-treatment scan, ≥2 new lesions are observed relative to the first post-treatment scan, which is confirmed on a subsequent scan ≥6 weeks later; the date of progression is the date of the post-treatment scan when ≥2 new lesions were first documented.\n* Progression of soft tissue lesions, as defined per PCWG3 modified RECIST v1.1\n* Death from any cause","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.84","spread":null},{"groupId":"OG001","value":"39.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.89","spread":null},{"groupId":"OG001","value":"13.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Greater Than (>) 50 Percent (%) Decrease in Prostate-Specific Antigen (PSA) From Baseline","description":"PSA response rate, defined as a \\> 50% decrease in PSA from baseline that is confirmed after ≥ 3 weeks by a consecutive confirmatory PSA measurement","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"24.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to PSA Progression, Assessed as Per PCWG3 Criteria","description":"In participants with no PSA decline from baseline, PSA progression is defined as a ≥25% increase and an absolute increase of ≥2 ng/mL above the baseline value, ≥12 weeks after baseline. In participants with an initial PSA decline from baseline, PSA progression is defined as a ≥25% increase and an absolute increase of ≥2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥3 weeks later.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participant With Objective Response, as Determined by the Investigator Through Use of PCWG3 Criteria","description":"Objective response rate in soft tissue lesions, defined as the percentage of participants with either a CR or PR on two consecutive occasions ≥ 6 weeks apart, as determined by the investigator through use of PCWG3 criteria","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"Verbatim description of adverse events will be coded to MedDRA preferred terms and graded according to NCI CTCAE v4.0.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.1","spread":null},{"groupId":"OG001","value":"51.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab","description":"Safety visit-Discontinued participants had these visits within approximately 120 days after the last dosing; Study Completion Pre-dose visit-Participants had these visits at the last treatment dosing, samples were taken before the last dosing; Early Discontinuation Pre-dose visit-Participants who discontinued the study had these visits within the 30 days after their last dosing but samples were takes before their last dosing; Study Completion visit-Participants had these visits at their last treatment dosing but samples were taken after their last dosing; Early Discontinuation visit-Participants who discontinued the study had the visits within the 30 days after their last dosing but samples were taken after their last dosing; Unscheduled and Unscheduled Pre-dose Visits- At these visits, participants' samples were collected without dosing event and before dosing dosing at a visit unscheduled per protocol respectively. Enzalutamide Arm had no Atezolizumab dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":"69.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":"79.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":"65.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":"305.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":"497.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":"144.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.69","spread":"1759.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":"1008.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":"106.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":"326.5"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab","description":"Safety visit-Discontinued participants had these visits within approximately 120 days after the last dosing; Study Completion Pre-dose visit-Participants had these visits at the last treatment dosing, samples were taken before the last dosing; Early Discontinuation Pre-dose visit-Participants who discontinued the study had these visits within the 30 days after their last dosing but samples were takes before their last dosing; Study Completion visit-Participants had these visits at their last treatment dosing but samples were taken after their last dosing; Early Discontinuation visit-Participants who discontinued the study had the visits within the 30 days after their last dosing but samples were taken after their last dosing; Unscheduled and Unscheduled Pre-dose Visits- At these visits, participants' samples were collected without dosing event and before dosing dosing at a visit unscheduled per protocol respectively. Enzalutamide Arm had no Atezolizumab dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":"26.5"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Enzalutamide","description":"Safety visit-Discontinued participants had these visits within approximately 120 days after the last dosing; Study Completion Pre-dose visit-Participants had these visits at the last treatment dosing, samples were taken before the last dosing; Early Discontinuation Pre-dose visit-Participants who discontinued the study had these visits within the 30 days after their last dosing but samples were takes before their last dosing; Study Completion visit-Participants had these visits at their last treatment dosing but samples were taken after their last dosing; Early Discontinuation visit-Participants who discontinued the study had the visits within the 30 days after their last dosing but samples were taken after their last dosing; Unscheduled and Unscheduled Pre-dose Visits- At these visits, participants' samples were collected without dosing event and before dosing dosing at a visit unscheduled per protocol respectively. Enzalutamide Arm had no Atezolizumab dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.51","spread":"406.4"},{"groupId":"OG001","value":"2.42","spread":"270.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"29.0"},{"groupId":"OG001","value":"13.8","spread":"20.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":"27.3"},{"groupId":"OG001","value":"16.0","spread":"19.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"103.7"},{"groupId":"OG001","value":"12.6","spread":"30.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"10.5","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of N-Desmethyl Enzalutamide","description":"Safety visit-Discontinued participants had these visits within approximately 120 days after the last dosing; Study Completion Pre-dose visit-Participants had these visits at the last treatment dosing, samples were taken before the last dosing; Early Discontinuation Pre-dose visit-Participants who discontinued the study had these visits within the 30 days after their last dosing but samples were takes before their last dosing; Study Completion visit-Participants had these visits at their last treatment dosing but samples were taken after their last dosing; Early Discontinuation visit-Participants who discontinued the study had the visits within the 30 days after their last dosing but samples were taken after their last dosing; Unscheduled and Unscheduled Pre-dose Visits- At these visits, participants' samples were collected without dosing event and before dosing dosing at a visit unscheduled per protocol respectively. Enzalutamide Arm had no Atezolizumab dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"NA"},{"groupId":"OG001","value":"0.03","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"33.1"},{"groupId":"OG001","value":"11.9","spread":"28.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"34.2"},{"groupId":"OG001","value":"10.9","spread":"29.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"36.8"},{"groupId":"OG001","value":"13.1","spread":"32.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"13.3","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab","description":"The numbers and proportions of ADA-positive participants and ADA-negative participants at baseline (baseline prevalence) and after baseline (post-baseline incidence) will be summarized by treatment group.\n\nEnzalutamide Arm has no Atezolizumab dosing therefore no participants to include here for Atezolizumab ADA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"320","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":139,"n":374},"commonTop":["Fatigue","Decreased appetite","Nausea","Asthenia","Arthralgia"]}}}